Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265091 | 0.90 | P2RY12 (0.49) | RARBDHODHRARAP2RY12PLA2G2A | |
| SCHEMBL1111239 | 0.84 | P2RY12 (0.52) | MCL1P2RY12PDE10A | |
| SCHEMBL5269568 | 0.83 | PLA2G2A (0.48) | RARBDHODHRARAP2RY12PLA2G2A | |
| SCHEMBL4271936 | 0.82 | NPC1 (0.55) | MCL1P2RY12 | |
| SCHEMBL4264916 | 0.81 | XDH (0.46) | RARBDHODHRARAPLA2G2A | |
| SCHEMBL2899930 | 0.80 | MCL1 (0.52) | MCL1PDE10A | |
| SCHEMBL4260900 | 0.79 | RARB (0.44) | RARBDHODHRARAP2RY12PLA2G2A | |
| SCHEMBL4262285 | 0.79 | MCL1 (0.49) | MCL1P2RY12 | |
| SCHEMBL14802124 | 0.76 | LTA4H (0.53) | DHODHPLA2G2A | |
| SCHEMBL4265711 | 0.76 | MCL1 (0.74) | MCL1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | RARB 517/4885DHODH 706/4885RARA 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.